The estimated Net Worth of David M Urso is at least $1.41 Million dollars as of 6 August 2018. Mr. Urso owns over 9,500 units of MEI Pharma Inc stock worth over $72,800 and over the last 11 years he sold MEIP stock worth over $34,010. In addition, he makes $1,307,950 as Chief Operating Officer and General Counsel at MEI Pharma Inc.
Sign up
Mr. Urso MEIP stock SEC Form 4 insiders trading
David has made over 1 trades of the MEI Pharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 9,500 units of MEIP stock worth $34,010 on 6 August 2018.
The largest trade he's ever made was selling 9,500 units of MEI Pharma Inc stock on 6 August 2018 worth over $34,010. On average, David trades about 679 units every 0 days since 2014. As of 6 August 2018 he still owns at least 24,106 units of MEI Pharma Inc stock.
You can see the complete history of Mr. Urso stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Urso biography
David M. Urso J.D. serves as Chief Operating Officer, General Counsel of the Company. Mr. Urso had been the Company’s Senior Vice President of Corporate Development and General Counsel since March 2014. Mr. Urso joined MEI Pharma with more than two decades of experience in the life science industry, most recently as Chief Operating Officer and General Counsel at Tioga Pharmaceuticals, a privately held drug development company he co-founded in 2005. Previously, he was a Principal at Forward Ventures, where he was responsible for identifying and developing life science venture capital investments. Prior to joining Forward Ventures in 2002, Mr. Urso was Director of Corporate Development and Legal Affairs at DNA Sciences, Inc. Previously, he worked as an attorney in the corporate securities and licensing groups at Wilson Sonsini Goodrich & Rosati LLP and Cooley Godward LLP, after beginning his career as a bench scientist at SmithKline Beecham and the University of Pennsylvania Medical School. Mr. Urso received a J.D. from Harvard Law School and a B.A. in Molecular Biology and Philosophy from Reed College.
What is the salary of David Urso?
As the Chief Operating Officer and General Counsel of MEI Pharma Inc, the total compensation of David Urso at MEI Pharma Inc is $1,307,950. There are 1 executives at MEI Pharma Inc getting paid more, with Daniel Gold having the highest compensation of $1,854,410.
How old is David Urso?
David Urso is 55, he's been the Chief Operating Officer and General Counsel of MEI Pharma Inc since 2018. There are 13 older and 2 younger executives at MEI Pharma Inc. The oldest executive at MEI Pharma Inc is Kevan Clemens, 75, who is the Independent Director.
What's David Urso's mailing address?
David's mailing address filed with the SEC is C/O MEI PHARMA, INC., 11455 EL CAMINO REAL, SUITE 250, SAN DIEGO, CA, 92130.
Insiders trading at MEI Pharma Inc
Over the last 12 years, insiders at MEI Pharma Inc have traded over $26,282,680 worth of MEI Pharma Inc stock and bought 597,450 units worth $2,541,200 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Leaf Ventures Ii, L.P.New L..., and Josiah T Austin. On average, MEI Pharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of $360,383. The most recent stock trade was executed by Funds Management Lp Anson A... on 22 September 2023, trading 48,060 units of MEIP stock currently worth $329,211.
What does MEI Pharma Inc do?
mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.
What does MEI Pharma Inc's logo look like?
Complete history of Mr. Urso stock trades at MEI Pharma Inc
MEI Pharma Inc executives and stock owners
MEI Pharma Inc executives and other stock owners filed with the SEC include:
-
Daniel Gold,
President, Chief Executive Officer, Director -
David Urso,
Chief Operating Officer, General Counsel -
Dr. Daniel P. Gold,
Pres, CEO & Director -
Brian Drazba,
Chief Financial Officer, Secretary -
David M. Urso B.A., Esq., J.D.,
COO & Gen. Counsel -
Robert Mass,
Chief Medical Officer -
Brian G. Drazba B.A., CPA, CPA,
CFO & Sec. -
Dr. Richard G. Ghalie,
Chief Medical Officer -
Dr. Robert D. Mass,
Strategic Advisor -
Charles Baltic,
Independent Director -
Nicholas Glover,
Independent Director -
Kevan Clemens,
Independent Director -
Frederick Driscoll,
Independent Director -
Tamar Howson,
Independent Director -
Cheryl Cohen,
Director -
Brian Powl,
Senior Vice President of Marketing -
Tina Clark Beamon Esq., J.D.,
Chief Compliance Officer -
Dr. Karen E. Potts Ph.D.,
Sr. VP of Regulatory Affairs -
Dr. Ofir Moreno,
Sr. VP of Pharmaceutical Sciences -
Jamie A. Tereschuck,
VP of HR -
David A. Walsey J.D., L.L.M.,
VP of IR & Corp. Communications -
Leaf Ventures Ii, L.P.New L...,
-
Ventures V, Llc Vivo,
-
Leah Rush Cann,
Director -
Thomas M. Zech,
Chief Financial Officer -
William Dodge Rueckert,
Director -
Ventures Vii, Llc Vivo,
-
Christine Anna White,
Director -
Ventures V, Llc Vivo Ventur...,
-
Leaf Ventures Ii, L.P.New L...,
-
Leaf Ventures Ii, L.P.New L...,
-
Ventures Vii, Llc Vivo Vent...,
-
Josiah T El Coronado Holdin...,
-
Leaf Ventures Ii, L.P.New L...,
-
Josiah T Austin,
10% owner -
Bryan Williams,
Director -
Ltd Novogen,
10% owner -
Sujay Kango,
-
Richard G Ghalie,
Chief Medical Officer -
Thomas C Reynolds,
-
Funds Management Lp Anson A...,
-
Funds, Lp Cable Car Capital...,
-
Steven D Wood,
-
James P Flynn,